Inventor
CHANG HWAI WEN
US54 patents
⚠️ This page may combine multiple inventors who share the name “CHANG HWAI WEN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BIOATLA LLC
14 patentsUS11111288B2Sep 7, 2021
Conditionally active chimeric antigen receptors for modified t-cells
BIOATLA LLC9 citations86
US9637734B2May 2, 2017
Mirac proteins
BIOATLA LLC5 citations84
US9856323B2Jan 2, 2018
Anti-CD22 antibodies
BIOATLA LLC10 citations82
US11279924B2Mar 22, 2022
Conditionally active polypeptides and methods of generating them
BIOATLA LLC3 citations73
US11254932B2Feb 22, 2022
Conditionally active biological proteins
BIOATLA LLC2 citations73
US11149088B2Oct 19, 2021
Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
BIOATLA LLC3 citations73
US10329556B2Jun 25, 2019
Conditionally active biological proteins
BIOATLA LLC2 citations73
US9637735B2May 2, 2017
Mirac proteins
BIOATLA LLC2 citations73
US9994841B2Jun 12, 2018
Mirac proteins
BIOATLA LLC1 citations63
US9982252B2May 29, 2018
Mirac proteins
BIOATLA LLC1 citations63
US11254742B2Feb 22, 2022
Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
BIOATLA LLC1 citations62
US10954288B2Mar 23, 2021
Modified antibody regions and uses thereof
BIOATLA LLC0 citations62
US10696750B2Jun 30, 2020
Multi-specific monoclonal antibodies
BIOATLA LLC1 citations62
US10563194B2Feb 18, 2020
Conditionally active biological proteins
BIOATLA LLC1 citations62
NOVARTIS AG
11 patentsUS9683048B2Jun 20, 2017
Antibody molecules to PD-1 and uses thereof
NOVARTIS AG115 citations98
US9815898B2Nov 14, 2017
Antibody molecules to PD-1 and uses thereof
NOVARTIS AG35 citations97
US10711060B2Jul 14, 2020
Antibody molecules to LAG-3 and uses thereof
NOVARTIS AG29 citations93
US9988452B2Jun 5, 2018
Antibody molecules to PD-L1 and uses thereof
NOVARTIS AG30 citations93
US9908936B2Mar 6, 2018
Antibody molecules to LAG-3 and uses thereof
NOVARTIS AG23 citations93
US10851165B2Dec 1, 2020
Antibody molecules to PD-L1 and methods of treating cancer
NOVARTIS AG10 citations83
US10752687B2Aug 25, 2020
Antibody molecules to PD-1 and uses thereof
NOVARTIS AG6 citations83
US11827704B2Nov 28, 2023
Antibody molecules to PD-1 and uses thereof
NOVARTIS AG2 citations72
US11413340B2Aug 16, 2022
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
NOVARTIS AG2 citations72
US12186278B2Jan 7, 2025
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
NOVARTIS AG0 citations62
US12252535B2Mar 18, 2025
Antibody molecules to LAG-3 and uses thereof
NOVARTIS AG0 citations61
BIOATLA INC
11 patentsUS11897959B2Feb 13, 2024
Anti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereof
BIOATLA INC2 citations73
US11851499B2Dec 26, 2023
Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof
BIOATLA INC2 citations73
US11773509B2Oct 3, 2023
Conditionally active polypeptides and methods of generating them
BIOATLA INC2 citations73
US11718844B2Aug 8, 2023
Mirac proteins
BIOATLA INC1 citations73
US11472876B2Oct 18, 2022
Conditionally active polypeptides
BIOATLA INC4 citations73
US12473360B2Nov 18, 2025
Multi-specific antibody constructs
BIOATLA INC0 citations62
US12427347B2Sep 30, 2025
Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof
BIOATLA INC0 citations62
US12311032B2May 27, 2025
Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
BIOATLA INC0 citations62
US12110611B2Oct 8, 2024
Conditionally active biological proteins
BIOATLA INC1 citations62
US11879011B2Jan 23, 2024
Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof
BIOATLA INC0 citations62
US11542332B2Jan 3, 2023
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
BIOATLA INC1 citations62
ARCH ONCOLOGY INC
4 patentsUS10259873B2Apr 16, 2019
Therapeutic CD47 antibodies
ARCH ONCOLOGY INC21 citations93
US10676524B2Jun 9, 2020
Therapeutic CD47 antibodies
ARCH ONCOLOGY INC2 citations72
US10669336B2Jun 2, 2020
Therapeutic CD47 antibodies
ARCH ONCOLOGY INC4 citations72
US11292834B2Apr 5, 2022
Therapeutic CD47 antibodies
ARCH ONCOLOGY INC0 citations61
VASCULOX INC
3 patentsSHORT JAY M
2 patentsCORVUS PHARMACEUTICALS INC
2 patentsFREY GERHARD
1 patentVENTER J CRAIG
1 patentSTRATAGENE INC
1 patentShowing the top 50 of 54 patents by PatentIndex Score.